Clinical Trial Update: Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone Therapy [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating bevacizumab in relapsed, hormone-refractory prostate cancer has completed. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: Barbara Ann Karmanos Cancer Institute | Conditions: Adenocarcinoma of the Prostate, Recurrent Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2014-07-08